MA52199A - Compositions et procédés de traitement de la dystrophie maculaire - Google Patents

Compositions et procédés de traitement de la dystrophie maculaire

Info

Publication number
MA52199A
MA52199A MA052199A MA52199A MA52199A MA 52199 A MA52199 A MA 52199A MA 052199 A MA052199 A MA 052199A MA 52199 A MA52199 A MA 52199A MA 52199 A MA52199 A MA 52199A
Authority
MA
Morocco
Prior art keywords
compositions
treatment
methods
macular dystrophy
dystrophy
Prior art date
Application number
MA052199A
Other languages
English (en)
Inventor
Robert Maclaren
De La Camara Cristina Martinez-Fernandez
Gregory S Robinson
Original Assignee
Nightstarx Ltd
Univ Oxford Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nightstarx Ltd, Univ Oxford Innovation Ltd filed Critical Nightstarx Ltd
Publication of MA52199A publication Critical patent/MA52199A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
MA052199A 2018-04-05 2019-04-05 Compositions et procédés de traitement de la dystrophie maculaire MA52199A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862653131P 2018-04-05 2018-04-05

Publications (1)

Publication Number Publication Date
MA52199A true MA52199A (fr) 2021-02-17

Family

ID=66223872

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052199A MA52199A (fr) 2018-04-05 2019-04-05 Compositions et procédés de traitement de la dystrophie maculaire

Country Status (21)

Country Link
US (2) US20190307900A1 (fr)
EP (1) EP3775233A1 (fr)
JP (1) JP2021520232A (fr)
KR (1) KR20210005040A (fr)
CN (1) CN113056561A (fr)
AU (1) AU2019247864A1 (fr)
BR (1) BR112020020204A2 (fr)
CA (1) CA3096088A1 (fr)
CL (1) CL2020002561A1 (fr)
CO (1) CO2020013690A2 (fr)
EA (1) EA202092069A1 (fr)
IL (1) IL277779A (fr)
JO (1) JOP20200253A1 (fr)
MA (1) MA52199A (fr)
MX (1) MX2020010477A (fr)
PE (1) PE20210918A1 (fr)
PH (1) PH12020551641A1 (fr)
RU (1) RU2020132890A (fr)
SG (1) SG11202009759SA (fr)
TW (1) TW202003052A (fr)
WO (1) WO2019195727A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019363593A1 (en) * 2018-10-25 2021-04-29 Takeda Pharmaceutical Company Limited AAV triple-plasmid system
WO2020140007A1 (fr) * 2018-12-28 2020-07-02 University Of Rochester Thérapie génique pour mutations dominantes best1
US20230112568A1 (en) * 2020-02-28 2023-04-13 The Trustees Of The University Of Pennsylvania Treating autosomal recessive bestrophinopathies and methods for evaluating same
CN111849998A (zh) * 2020-07-29 2020-10-30 武汉纽福斯生物科技有限公司 编码人卵黄状黄斑病蛋白1的核酸分子及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2762864T3 (es) * 2008-06-18 2020-05-26 Oxford Biomedica Ltd Purificación de virus
US9163259B2 (en) * 2012-05-04 2015-10-20 Novartis Ag Viral vectors for the treatment of retinal dystrophy
CA2930282A1 (fr) * 2013-11-20 2015-05-28 Fondazione Telethon Proteines artificielles se liant a l'adn et leurs utilisations
EP3077520A1 (fr) * 2013-12-06 2016-10-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour exprimer un polynucléotide d'intérêt dans l'épithélium pigmentaire rétinien d'un sujet
GB201322798D0 (en) * 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
AU2016227668B2 (en) * 2015-03-03 2019-06-27 Fondazione Telethon Multiple vector system and uses thereof
EP3374494A4 (fr) * 2015-11-11 2019-05-01 Coda Biotherapeutics, Inc. Compositions crispr et leurs méthodes d'utilisation pour la thérapie génique

Also Published As

Publication number Publication date
PH12020551641A1 (en) 2021-07-26
BR112020020204A2 (pt) 2021-01-19
US20190307900A1 (en) 2019-10-10
JP2021520232A (ja) 2021-08-19
TW202003052A (zh) 2020-01-16
CA3096088A1 (fr) 2019-10-10
PE20210918A1 (es) 2021-05-19
CN113056561A (zh) 2021-06-29
CO2020013690A2 (es) 2021-04-19
SG11202009759SA (en) 2020-10-29
CL2020002561A1 (es) 2021-04-23
MX2020010477A (es) 2021-03-02
KR20210005040A (ko) 2021-01-13
EA202092069A1 (ru) 2021-03-12
IL277779A (en) 2020-11-30
US20230149566A1 (en) 2023-05-18
EP3775233A1 (fr) 2021-02-17
AU2019247864A1 (en) 2020-10-22
RU2020132890A (ru) 2022-05-06
JOP20200253A1 (ar) 2020-10-04
WO2019195727A1 (fr) 2019-10-10

Similar Documents

Publication Publication Date Title
MA51103A (fr) Compositions et procédés de traitement de l'atrophie musculaire et de la dystrophie myotonique
MA43283A (fr) Procédés et compositions pour le traitement du cancer
MA46427A (fr) Compositions d'oligonucléotides et procédés associés
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
MA42819A (fr) Procédés pour le traitement d'infections virales à arenaviridae et coronaviridae
MA52199A (fr) Compositions et procédés de traitement de la dystrophie maculaire
MA47613A (fr) Compositions et procédés de traitement du cancer
MA45270A (fr) Compositions d'oligonucléotides et procédés associés
MA51306A (fr) Compositions et procédés améliorés pour le traitement du déficit en ornithine transcarbamylase
MA49069A (fr) Procédés et compositions pour le traitement d'apnée du sommeil
MA42439A (fr) Agents, utilisations et procédés pour le traitement d'une synucléinopathie
MA56212A (fr) Compositions et méthodes de traitement du cancer
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
MA53558A (fr) Compositions et procédés pour le traitement d'infections virales
MA53939A (fr) Compositions hémostatiques et leurs procédés de fabrication
MA55087A (fr) Compositions et procédés de traitement de laminopathies
MA45675A (fr) Méthodes et compositions permettant le traitement du cancer
MA53445A (fr) Procédés et compositions pour la modification de plantes
MA47172A (fr) Compositions et procédés de traitement des inflammations intestinales et du cancer du côlon
MA45552A (fr) Compositions destinées au traitement de l'amylose
MA53741A (fr) Procédés de traitement de troubles myéloprolifératifs
ZA202100703B (en) Compositions and methods for treating inflammasome related diseases or conditions
MA46586A (fr) Compositions de terlipressine et leurs procédés d'utilisation
MA45982A (fr) Compositions de neurostéroïdes et leurs procédés d'utilisation
MA51307A (fr) Compositions laitières fermentées et procédés de préparation de celles-ci